Impaired immunity and tissue hypoxia-ischemia are strongly linked with Streptococcus pneumoniae pathogenesis in patients with sickle cell anemia. Perfluorocarbon emulsions (PFCEs) have high O 2 -dissolving capacity and can alleviate tissue hypoxia. Here, we evaluate the effects of intravenous PFCE therapy in transgenic sickle cell (HbSS) mice infected with S. pneumoniae. HbSS and C57BL/6 (control) mice intravenously infected with S. pneumoniae were treated intravenously with PFCE or phosphate-buffered saline (PBS) and then managed in either air/O 2 (FiO 2 proportion, 50%; hereafter referred to as the PFCE-O 2 and PBS-O 2 groups) or air only (hereafter, the PFCE-air and PBS-air groups) gas mixtures. Lungs were processed for leukocyte and bacterial counts and cytokine measurements. HbSS mice developed severe pneumococcal infection significantly faster than C57BL/6 mice (Kaplan-Maier analysis, P < .05). PFCE-O 2 -treated HbSS mice had significantly better survival at 72 hours than HBSS mice treated with PFCE-air, PBS-O 2 , or PBS-air (P < .05). PFCE-O 2 -treated HbSS mice also had significantly lower pulmonary leukocyte counts, lower interleukin 1β and interferon γ levels, and higher interleukin 10 levels than PFCE-air-treated HbSS mice. Clearance of S. pneumoniae from lungs of HbSS mice or C57BL/6 mice was not altered by PFCE treatment. Improved survival of PFCE-O₂-treated HbSS mice infected with S. pneumoniae is associated with altered pulmonary inflammation but not enhanced bacterial clearance.
Sickle cell anemia is the most common form of sickle cell disease [1] . Individuals with homozygous sickle cell disease (HbSS) produce a variant hemoglobin that aggregates under conditions of low oxygen [2, 3] . Red blood cells (RBCs) with HbSS aggregates deform to a characteristic sickle shape and are significantly less plastic [2] [3] [4] . The alteration in mechanical properties predisposes sickled RBCs to sticking within capillaries, thereby causing obstruction to blood flow and hypoxicischemic organ damage [4] .
Clinically, sickle cell anemia is a chronic disease punctuated by acute crises [4] [5] [6] [7] [8] [9] . Vasoocclusive crises cause a variety of symptoms and syndromes [5] [6] [7] [8] [9] .
Individuals with HbSS are also prone to bacterial sepsis, particularly Streptococcus pneumoniae infection [10, 11] . Streptococcus pneumoniae infection can lead to hypoxemia and precipitate vasoocclusive events in tissues, to produce a prognostically poor clinical scenario as, for example, in acute chest syndrome [5, 6, [8] [9] [10] [11] . Initial treatment of acute crises such as acute chest syndrome includes O 2 therapy, intravenous fluids, and broad-spectrum antibiotics [5, [8] [9] [10] [11] . Individuals who do not respond promptly or who deteriorate are treated with top-up or exchange blood transfusions [12] , which, while effective and lifesaving, are associated with adverse reactions, including transfusion-related acute lung injury [13] . Hence, management of life-threatening vasoocclusive/infective crises remains a challenge, and better treatments are needed to improve outcomes [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] .
In HbSS disease, blood transfusion therapy reduces the proportion of circulating RBCs containing variant hemoglobin [12] . However, it does not readily improve oxygenation and/or perfusion of tissues whose capillary bed is occluded by sickled RBCs prior to transfusion [4] [5] [6] [7] [8] [9] . Here, cellular injury continues until perfusion is restored fully.
Oxycyte (Oxygen Biotherapeutics, Morrisville, North Carolina), a third-generation perfluorocarbon emulsion (PFCE), is composed of particles (diameter, 0.2 μm) that have a hydrophobic organofluorine ( perfluoro[tert-butylcyclohexane], C 10 F 20 ) core and a hydrophilic outer coat (egg yolk phospholipids) suspended in a water-based solution [14] [15] [16] . It has high gasdissolving capacity and, unlike hemoglobin, has a linear relationship between oxygen partial pressure ( pO 2 ) and oxygen content [14] [15] [16] . Although whole blood has a higher absolute oxygen content than PFCE, O 2 release from PFCE is almost complete in the presence of a high PO 2 gradient and usually exceeds the amount released by hemoglobin [16] . Presently, Oxycyte is undergoing evaluation in a phase 2 study of patients with traumatic brain injury at risk of hypoxic-ischemic brain damage [17] . Although PFCE is often suggested as an alternative to blood transfusion, little is known about its therapeutic potential in HbSS. In this proof-of-concept study, we set out to determine whether intravenous PFCE therapy alters the clinical course of S. pneumoniae infection in transgenic sickle cell (HbSS) mice.
MATERIALS AND METHODS

Ethics Approval, Animals, and Bacterial Strains
All animal experiments were performed at a designated facility in the University of Leicester and in accordance to United Kingdom Home Office guidelines with ethics approval from The University of Leicester Ethics Committee. HbSS mice (Hbatm1-Paz Hbbtm1Tow Tg(HBA-HBBs)41Paz/J) and background strain C57BL/6 mice [18] were purchased from The Jackson Laboratory (United States), and C57BL/6 (control) mice were purchased from Charles River (United Kingdom). Genotypes of mice bred from transgenic mating pairs were established by polymerase chain reaction (PCR) analysis. Briefly, DNA from an ear biopsy specimen was prepared using the QiaPrep DNeasy Blood and Tissue Kit (Qiagen, West Sussex, United Kingdom). Genomic DNA was then amplified using MyTaq Red DNA polymerase (Bioline, London, United Kingdom) and reverse and forward sequence complementary DNA primers for HbB and HbS (Eurofins Genetic Services, London, United Kingdom). The amplified products were visualized using agarose Figure 1 . Figure 1 outlines the experimental schema. Transgenic sickle cell (HbSS) mice were bred, genotyped and grown to maturity before experiments. HbSS and C57 mice were placed into one of three groups (n = 6 from each strain) at point [E] in the schema. Group (a) consisted of mice that were neither infected with Streptococcus pneumoniae nor injected with phosphate-buffered saline (PBS) or perfluorocarbon emulsion (PFCE). Group (b) consisted of mice treated with PBS or PFCE but not infected with S. pneumoniae. Group (c) consisted of mice infected with S. pneumoniae and treated with PBS or PFCE in air or O 2 . Mice were euthanized at 72 hours after entry into an experiment. electrophoresis and ethidium bromide as described by Sambrook et al [19] . S. pneumoniae serotype 2, strain D39, was prepared as described previously [18] .
Experimental Design
The experimental design is illustrated in Figure 1 . Mice were infected with S. pneumoniae by injecting 100 µL of inoculum (2-6.4 × 10 5 colony-forming units [CFU]/mL) into the tail vein of anesthetized animals. Three hours after infection, mice were reanesthetized and given intravenous doses (3 mL/ kg) of phosphate-buffered saline (PBS) or PFCE (Oxycyte) via the tail vein and recovered in ambient-air chambers or chambers supplied with supplemental oxygen (FiO 2 proportion, 50%). Three hours following PBS or PFCE injection, mice receiving supplemental oxygen were transferred to ambient air conditions. Animals were euthanized 72 hours after infection or immediately on developing severe lethargy as previously described [20] . Lungs of euthanized mice were processed for histologic analysis, white blood cell counts, cytokine analysis, and determination of S. pneumoniae colony counts. Blood specimens were aspirated via a cardiac puncture for colony count determinations.
Lung Histological Analysis
The left lungs of mice were fixed in formalin, processed into paraffin wax, cut (4-6 µm thick), mounted onto slides, and stained with hematoxylin-eosin. Histopathologic analysis was performed using low-power (×10 and ×20) and high-power (×50 and ×100) objective lenses and a graticule. Lung injury was assessed by quantifying healthy alveoli and alveoli with exudate, hemorrhaging, or inflammatory cells (macrophages, neutrophils, and lymphocytes were identified using nuclear morphology). The overall percentage of alveoli in a lung section with the histologic abnormality was converted to a linear score (range, 0-5), referred to as the airspace score, with 0 indicating absence of the variable and 5 indicating inflammation present in 81%-100% of alveoli. Three lung sections from each were used to determine an average score. Each lung section was scored separately by 2 of the authors (N. H. and H. P.), and the average was used as the final airspace score.
Lung White Blood Cell Counts
Lung differential white blood cell counts were performed using cell homogenates of right lung and the Calibur FACS system with Cell Quest Pro software (Becton Dickinson, Cowley, United Kingdom), as previously described [21] . Lung cells were incubated with fluorophore-conjugated antibodies directed against mouse neutrophil (Gr-1/Ly-6G-phycoerythrin-cy7), macrophage (F4/80-allophycocyanin), T-cell (CD3-phycoerythrin), and B-cell (CD19-FITC) antigens (all purchased from Biolegend, San Diego, California).
Estimation of S. pneumoniae Recovered From Lung Tissue and Blood and Lung Cytokine Assays
Streptococcus pneumoniae were recovered from whole-blood specimens and from the right lung homogenized in PBS. Colony counts were performed as previously described [22, 23] . Cytokine quantifications were performed using homogenized right lung and sandwich enzyme-linked immunosorbent assay (Qiagen, Valencia, California).
RBC Sickling in HbSS Mice
The percentage of sickled RBCs in HBSS mice was determined using glass slide blood smears stained with Giemsa stain (Sigma, Poole, United Kingdom).
Effect of PFCE on S. pneumoniae In Vitro
Streptococcus pneumoniae was cultured in chemically defined medium (CDM) [23] at 37°C and then transferred into tubes containing varying concentrations of PFCE (0%-4% v/v) in CDM. Culture samples were removed at hourly intervals for 10 hours and plated overnight on blood agar for colony counting [23, 24] .
Statistical Analysis
All statistical analyses were performed using GraphPad Prism software (La Jolla, California). Kaplan-Meier survival curves were compared using the log-rank Mantel-Cox test. Withingroup comparisons of white blood cell and cytokine data were performed using 1-way analysis of variance. Between-group comparisons were performed using the Student t test with the Welch correction for different variances. A P value of < .05 was considered significant.
RESULTS
PFCE-O 2 Therapy Reduces the Susceptibility of HbSS Mice to S. pneumoniae Infection
All HbSS mice infected with S. pneumoniae and treated with PBS-air developed signs of severe sepsis within 72 hours and were euthanized before the end of the experiment. Pneumococcus-infected C57BL/6 mice treated with PBS-air survived significantly better than HBSS littermates, with only 50% of animals euthanized before 72 hours (P < .05, by Kaplan-Meier analysis; Figure 2A ). C57B6/L mice treated with PBS-air also survived significantly better than HbSS mice treated with PFCE-air (P < .05, by Kaplan-Meier analysis; Figure 2A ). PFCE-airtreated C57BL/6 mice were more susceptible to S. pneumoniae than PBS-treated controls (P < .05, by Kaplan-Meier analysis; Figure 2A ), whereas PFCE-air and PBS-air-treated HbSS mice had similar survival (P > .05, by Kaplan-Meier analysis). HbSS mice treated with PFCE-O 2 had significantly better survival than HbSS littermates treated with PFCE-air, PBS-O 2 , or PBS-air (P < .05 for all comparisons, by Kaplan-Meier analysis; Figure 2B ). In contrast, pneumococcus-infected C57BL/6 mice treated with PFCE-O 2 or PFCE-air had significantly worse survival than infected C57BL/6 mice treated with PBS-O 2 or PBS-air (P < .05 for all comparisons, by Kaplan-Meier analysis; Figure 2C ).
PFCE-O 2 Therapy Does Not Attenuate Lung Injury in S. pneumoniae-Infected HbSS Mice
Uninfected, untreated HbSS mice (the nil group; Figure 3A) had evidence of acute lung injury, characterized by increased inflammatory cells, hemorrhaging, and exudates (P < .05). These mice also had evidence of widespread lung fibrosis (data not shown). None of these features were present in uninfected, untreated C57BL/6 mice ( Figure 3C ).
S. pneumoniae infection of HbSS mice was associated with an increase in airspace exudates, inflammatory cells and hemorrhage, compared with infected C57BL/6 mice ( Figure 3A and 3C). S. pneumoniae-infected HbSS mice treated with PFCE-O 2 had lung inflammation scores similar to those treated with PFCE-air (P > .05; Figure 3B ).
PFCE-O 2 Therapy Attenuates Pulmonary Leukocytosis in S. pneumoniae-Infected HbSS Mice
Untreated, uninfected HbSS mice had higher pulmonary macrophage, neutrophil, T-cell, and B-cell counts than untreated, uninfected C57BL/6 mice (P < .05 for all comparisons; Supplementary Infected HbSS mice treated with phosphate-buffered saline (PBS)-air also had increased number of airspaces containing hemorrhaging, exudates, and inflammatory cells, compared with HbSS mice in the nil group (P < .05). B, Infected, PBS-air-treated HbSS mice had similar lung injury scores to infected PFCE-air-treated HbSS mice (P > .05). Infected, PFCE-O 2 -treated HBSS mice had similar lung injury scores to infected PFCE-air-treated HbSS mice (P > .05). C, In contrast, peripheral airspaces of uninfected, untreated C57B6/L mice (NIL) did not contain exudates or hemorrhage. C57B6/L mice infected with SP and treated with PBS had increased number of airspaces containing hemorrhaging, exudates, and inflammatory cells, compared with C57B6/L mice in the nil group (P < .05). Lung injury scores were not significantly different in pneumococcus-infected C57B6/L mice treated with PBS-air or PFCE-air (P > .05). There were 6 animals in each treatment group. Survival over 72 hours among HbSS and C57BL/6 mice managed in air or oxygen and treated with phosphate-buffered saline (PBS) or PFCE 3 hours after infection with S. pneumoniae. A, PBS-air-treated C57BL/6 mice (white squares) survived significantly better than PBS-air-treated HbSS mice (black circles), PFCE-air-treated HbSS mice (white circles), and PFCE-air-treated C57BL/6 mice (black triangles). P < .05 for each comparison. B, PFCE-O 2 -treated HbSS mice (white triangles) died significantly later than HBSS mice treated with PBS-air (white squares), PFCE-air (white circles), or PBS-O 2 (black circles). P < .05 for each comparison. C, C57BL/6 mice treated with PBS-air (black triangles) or PBS-O 2 (white circles) survived longer than C57BL/6 mice treated with PFCE-air (black circles) or PFCE-O 2 (white squares). P < .05 for each comparison. There were 6 animals in each treatment group. Figure 1A-1D) . Infection with S. pneumoniae led to a significant increase in pulmonary macrophage, neutrophil, T-cell, and B-cell counts in both mouse strains (P < .05 for all comparisons; Supplementary Figure 1A-1D ). There were no statistically significant between-or within-strain differences in white blood cell counts (all subsets) among PFCE-and PBS-treated mice (P > .05).
Infected HbSS mice treated with PFCE-O 2 had significantly lower macrophage, neutrophil, T-cell, and B-cell counts in the lungs than PFCE-air or PBS-O 2 -treated HbSS mice (P < .05 for all comparisons; Figure 4A , 4C, 4E, and 4G). Infected C57BL/6 mice treated with PFCE-air or PFCE-O 2 had significantly lower lung macrophage and neutrophil counts than PBS-air or PBS-O 2 -treated C57B6/L littermates (P < .05; Figure 4B and 4D). There were no differences in T-cell and B-cell counts in infected C57BL/6 mice in comparisons involving all treatments (P < .05; Figure 4F and 4H).
PFCE-O 2 Therapy Attenuates the Proinflammatory Cytokine Milieu in Lungs of HbSS Mice Infected with S. pneumoniae
Untreated, uninfected HbSS mice had significantly higher pulmonary levels of TNF-α, IL-1β, and IL-6 and significantly lower levels of IL-10 than untreated, uninfected C57B6/L mice (P < .05; Supplementary Figure 2) . Among infected PFCEtreated mice managed in air, there were no significant differences in levels of all other assayed cytokines between the HbSS and C57B6/L groups (P > .05 for each comparison; Supplementary  Figures 2) .
At the time of death, infected HbSS mice treated with PBS-O 2 had significantly higher levels of TNF-α and IL-6 than those treated PFCE-air or PFCE-O 2 (P < .05 for each comparison; Figure 5A and 5B). However, TNF-α and IL-6 levels in HbSS mice treated with PFCE-O 2 were not significantly different from levels in mice treated with PFCE-air (P > .05 for each comparison). Infected PFCE-O 2 -treated HbSS mice had significantly lower levels of pulmonary MIP-1α, IFN-γ, and IL-1β ( Figure 5C -E) than either PFCE-air-or PBS-O 2 -treated littermates (P < .05 for each comparison). In addition, PFCE-O 2 -treated HbSS mice had higher IL-10 levels ( Figure 5F ) than PFCE-air-or PBS-O 2 -treated mice (P < .05 for each comparison; Figure 5D ).
Infected C57BL/6 mice treated with PFCE-O 2 and PFCEair had significantly lower IL-6 ( Figure 5B ) and MIP-1α 
. Perfluorocarbon emulsion (PFCE)-O 2 therapy attenuates the influx of neutrophils, T cells, and B cells into lungs of transgenic sickle cell (HbSS)
mice but not C57BL/6 mice infected with Streptococcus pneumoniae. Fluorescence-activated cell sorter-determined neutrophil, macrophage, T-cell, and Bcell counts from lungs of HbSS (A, C, E, and G) and C57BL/6 (B, D, F, and H) mice infected with S. pneumoniae, managed in air or O 2 , and treated with PFCE or phosphate-buffered saline (PBS). Box and whisker plots represent ranges, with mean values shown by horizontal bars. Pneumococcus-infected HbSS mice treated with PFCE-O 2 had significantly lower pulmonary neutrophil, macrophage, T-cell, and B-cell counts (A, C, E, and G) than infected HbSS littermates treated with PFCE-air. Pneumococcus-infected C57BL/6 mice treated with PFCE-O 2 had leukocyte counts similar to those of infected littermates treated with PFCE-air (B, D, F, and H). Pneumococcus-infected PFCE-air-or PFCE-O 2 -treated C57BL/6 mice had significantly lower neutrophil and macrophage cell counts than PBS-air-or PBS-O 2 -treated littermates (B and D). There were 6 animals in each treatment group. *P < .01.
( Figure 5C ) levels, compared with PBS-O 2 -treated mice (P < .05). There were no significant differences in levels of all other assayed cytokines in C57B6/L mice in comparisons of different treatments (P > .05 for each comparison; Figure 5A , 5C, and 5D-5F).
CFU Counts From Blood and Lungs of S. pneumoniae-Infected HbSS and C57BL/6 Mice
There were no significant differences in blood or lung CFU counts at the time of death in comparisons of PFCE and PBS treatment groups among HbSS or in C57BL/6 mice managed in air or supplemental O 2 (P > .05; Figure 6A -6D).
PFCE Does Not Enhance the S. pneumoniae Growth Rate In Vitro
Over a 10-hour incubation period, S. pneumoniae cultures placed in CDM medium with or without PFCE exhibited a >10-fold increase in CFU counts ( Table 1 ). The growth rate and generation times of cultures grown in CDM medium only and those containing PFCE were not significantly different (P > .05).
PFCE Reduces RBC Sickling in HbSS Mice Infected with S. pneumonia
Blood specimens from HbSS mice treated with PFCE and infected with S. pneumoniae had a lower percentage of sickled RBCs than blood specimens from HbSS mice treated with PBS (P < .05; Supplementary Figure 3) . The percentage of sickled RBCs in blood specimens from HbSS mice treated with PFCE-O 2 was not statistically different (P > .05) from the percentage of sickled RBCs in blood specimens from littermates treated with PFCE-air (Supplementary Figure 3A) .
DISCUSSION
This study was designed to test the hypothesis that treatment with a third-generation PFCE, Oxycyte, attenuates S. pneumoniae infection in HbSS mice as a result of improved O 2 delivery. Intravenous PFCE therapy is linked with immune system and complement activation [15, 16] . Hence, we compared the outcome of S. pneumoniae infection in PFCE-O 2 -and PFCEair-treated mice. Our data show that intravenous PFCE therapy attenuates S. pneumoniae infection only in HbSS mice treated There were no differences in pulmonary cytokine levels between pneumococcus-infected C57BL/6 mice treated with PFCE-O 2 and those treated with PFCE-air. C57BL/6 mice treated with PFCE and managed in air or O 2 had significantly lower levels of IL-6 and MIP-1α than PBS-air-and PBS-O 2 -treated C57BL/6 mice. Levels of TNF-α, IL-1β, and IFN-γ were similar in pneumococcal-infected C57BL/6 mice irrespective of treatment regimen. There were 6 mice in each treatment group. *P < .01.
with supplemental oxygen, consistent with the original hypothesis. The improved survival of PFCE-O 2 -treated HbSS mice was associated with a reduced pulmonary inflammatory response but no change in clearance of S. pneumoniae from lungs or blood. Since PFCE-O 2 -treated C57BL/6 mice were more susceptible to infection, these observations suggest that tissue hypoxia plays a more significant role in the pathophysiology of S. pneumoniae infection in HbSS mice than in infected control mice.
The HbSS (Paszty) mice used in this study (background strain C57BL/6) express human α-, γ-, and βS-globin [18] and produce RBCs that are prone to sickling. As a consequence, the mice are chronically anemic and have a blood O 2 carrying capacity that is approximately 50% of that for wild-type mice [18] . At the time of death, lungs of uninfected HbSS mice were found to contain inflammatory cells, hemorrhages, and exudates, whereas lungs of uninfected C57BL/6 mice were completely normal ( Figure 3 and Supplementary Figure 1) . Moreover, compared with uninfected C57BL/6 mice, uninfected HbSS mice had higher pulmonary neutrophil, macrophage, T-cell, and B-cell counts ( Figure 5 ) and higher levels of TNF-α, IL-1β, and IL-6 (Supplementary Figure 2 and 3) . In contrast, pulmonary IL-10 levels were higher in uninfected C57BL/6 mice, compared with uninfected HbSS mice (Supplementary Figure 2) . This constellation of features is commonly associated with acute pulmonary inflammation. However, uninfected HbSS mice had evidence of chronic disease, manifest as pulmonary fibrosis (data not shown), a finding also reported by other groups [25, 26] . We did not observe any outward signs of acute illness in uninfected HbSS mice. Taken together, the observations suggest that low-grade and persistent inflammatory processes contribute to the development of pulmonary fibrosis in HbSS mice.
Following infection with S. pneumoniae, HbSS animals died earlier than C57BL/6 mice, indicating, as in human HbSS, an increased susceptibility to pneumococcal infection. In both HbSS and C57BL/6 mice, infection with S. pneumoniae led to a significant influx of all leukocyte subsets and a proinflammatory cytokine milieu in lungs. The magnitude of each of the measured inflammatory markers was similar in both mice. Figure 6 . Streptococcus pneumoniae colony counts from cultured blood and lungs are unaffected by perfluorocarbon emulsion (PFCE) therapy. Panels show S. pneumoniae colony counts from agar plates cultured overnight with blood (A and B) or lung homogenate (C and D) from transgenic sickle cell (HbSS) mice or C57BL/6 mice treated with phosphate-buffered saline (PBS) or PFCE and managed in air or O 2 . Treatment with PBS or PFCE and mouse strain were not associated with significant differences in S. pneumoniae colony counts obtained from blood or lung samples taken at the time of death (P > .05). There were 6 mice in each treatment group. Abbreviation: CFU, colony-forming units.
Thus, the level of pulmonary inflammation does not explain the increased susceptibility of HbSS mice to pneumococcal infection.
A more complex pathophysiological process is likely to account for differences in outcomes between HbSS and C57BL/ 6 mice infected with S. pneumoniae. Pneumococcus-induced lung inflammation and injury is recognized to cause ventilation-perfusion mismatch and, thereby, systemic hypoxemia [8, 9] . In HbSS mice, systemic hypoxemia will trigger RBC sickling and vascular occlusion [27, 28] . Without treatment, this potentially self-perpetuating scenario can lead to widespread tissue hypoxia-ischemia and, ultimately, multiorgan failure and death. Other factors, such as restrictive lung disease due to pulmonary fibrosis, reduced O 2 -carrying capacity, and increased susceptibility to sepsis owing to splenic dysfunction, are also likely to contribute to the vulnerability of HbSS mice to pneumococcal infection.
Treatment of HbSS mice with PFCE-O 2 greatly increased their resistance to pneumococcal disease. Improved survival (Figure 2B ) was associated with lower pulmonary leukocyte counts, lower levels of proinflammatory cytokines, and higher levels of the antiinflammatory cytokine IL-10 ( Figure 5 ). These findings are consistent with the hypothesis that both proinflammatory and antiinflammatory mediators have a role in recovery from pneumococcal infection [22, 29] and correlate with those of Rosch et al [25] and Lebensburger et al [26] , who found that survival of pneumococcus-infected HbSS mice is strongly associated with recruitment of neutrophils into lungs. Oxygen delivery by PFCE seems to be the primary driver for the dampening of the inflammatory response in HbSS mice, since the percentage of sickle RBCs in HbSS mice treated with PFCE-air was almost as low as that in HbSS mice treated with PFCE-O 2 .
Our data do not indicate that PFCE treatment affects the virulence of S. pneumoniae because lung homogenate and blood cultures from PBS-treated and PFCE-treated C57B6/L mice produced similar colony counts (Figure 6 ). In addition, the growth rate and generation time of S. pneumoniae cultured in the presence of PFCE were similar to the growth rate of bacteria grown in CDM alone (Supplementary Table 1) .
In the absence of extra O 2 , PFCE therapy was associated with a decreased percentage of sickled RBCs in pneumococcusinfected HbSS mice (Supplementary Figure 3) . In addition, survival of pneumococcus-infected, PFCE-treated C57BL/6 mice was lower than that for PBS-treated infected littermates. There are few data to account for the actions of PFCE on RBC sickling in HbSS mice exposed to air. It is possible that that the PFCE particles in Oxycyte reduce RBC sickling by entering RBCs and then directly interacting with HbSS. An alternative explanation is that PFCE particles increase O 2 flux from RBCs to tissues without lowering the RBC pO 2 [15, 16] . Hence, in the presence of PFCE, RBCs transit capillaries (where sickling is most likely to occur) with a higher PO 2 than would otherwise be the case and, as a result, have a reduced sickling propensity. However, if operating, neither mechanism was sufficient to increase survival of PFCE-air-treated infected HBSS mice, compared to their PBS-air-treated littermates.
The data presented here suggest that that treatment with PFCE-O 2 improves tissue oxygenation in pneumococcusinfected HBSS mice. Future studies should focus on whether circulating PFCE particles loaded with O 2 improve tissue O 2 levels through stabilizing HbSS and decreasing RBC sickling or by increasing O 2 flux from RBCs to cells or through improved gas exchange in lungs. The effects of PFCE-O 2 on lung neutrophils and macrophages also need further investigation.
To our knowledge, this is the first study to assess the effects of intravenous PFCE therapy in a preclinical model of HbSS. It provides much needed data about the efficacy of PFCEs, as requested by regulatory agencies [30] . Our findings indicate that relief of tissue hypoxia occurs after treatment with PFCE and that supplemental O 2 improves outcomes of S. pneumoniae infection in HbSS mice. As such, the findings suggest that intravenous PFCE therapy may be a useful adjunct to managing lifethreatening sickle crises.
Supplementary Data
Supplementary materials are available at The Journal of Infectious Diseases online (http://jid.oxfordjournals.org). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyedited. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author. There was no significant difference in growth rate or generation time of bacteria cultured in CDM alone or with PFCE (P > .05). The growth rate and generation time for each culture condition represent the mean change in bacterial colony forming units (log CFU/ml) / hour and the mean population doubling time, respectively. There was no significant difference in growth rate or generation time of bacteria cultured in CDM medium alone or in CDM containing PFCE (P > .05).
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